Formononetin


Curated chemical-gene interactions from CTD
Entrez gene IDGene symbolInteraction typeReference
10628 TXNIP Increases expression PMID:37793997
11254 SLC6A14 Decreases expression PMID:37793997
1244 ABCC2 Decreases expression PMID:23867903
1374 CPT1A Increases expression PMID:37793997
1543 CYP1A1 Increases expression PMID:28985473; PMID:37793997
1544 CYP1A2 Decreases activity PMID:26278343
1545 CYP1B1 Increases expression PMID:28985473
1565 CYP2D6 Decreases activity PMID:26278343
196 AHR Increases activity PMID:28985473
2056 EPO Increases expression PMID:21309574; PMID:37348668
2099 ESR1 Increases activity PMID:16076101; PMID:9751507
2100 ESR2 Increases activity PMID:16076101; PMID:9751507
3091 HIF1A Increases expression PMID:21309574; PMID:37348668; PMID:37348668
3565 IL4 Increases expression PMID:16108819
4148 MATN3 Decreases expression PMID:37793997
4193 MDM2 Increases expression PMID:28414026
4194 MDM4 Increases expression PMID:28414026
4363 ABCC1 Affects activity PMID:15796199
4363 ABCC1 Decreases expression PMID:23867903
4846 NOS3 Increases activity PMID:19570671
4846 NOS3 Increases expression PMID:19570671
5225 PGC Decreases expression PMID:37793997
5243 ABCB1 Decreases activity PMID:15796199; PMID:27996361
5243 ABCB1 Increases expression PMID:23867903
54658 UGT1A1 Increases expression PMID:37793997
57016 AKR1B10 Increases expression PMID:37793997
595 CCND1 Increases expression PMID:28414026
596 BCL2 Decreases expression PMID:23867903
6582 SLC22A2 Decreases expression PMID:28414026
6876 TAGLN Decreases expression PMID:37793997
7157 TP53 Decreases expression PMID:28414026
836 CASP3 Increases activity PMID:23867903
836 CASP3 Increases expression PMID:23867903
841 CASP8 Increases activity PMID:23867903
841 CASP8 Increases expression PMID:23867903
842 CASP9 Increases activity PMID:23867903
842 CASP9 Increases expression PMID:23867903
891 CCNB1 Increases expression PMID:28414026
9724 UTP14C Decreases expression PMID:37793997

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.